Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 2/2019

17.09.2018

Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis

verfasst von: A. M. Buchanan-Hughes, M. Buti, K. Hanman, B. Langford, M. Wright, L. A. Eddowes

Erschienen in: Quality of Life Research | Ausgabe 2/2019

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Purpose

Chronic hepatitis C infection and its treatment can considerably affect patients’ health-related quality-of-life (HRQoL). This study aimed to identify and summarise the current evidence base for health state utility values (HSUVs) in patients with chronic hepatitis C infection, generated using the EuroQol 5-dimensions (EQ-5D) questionnaire.

Methods

MEDLINE, Embase, the Cochrane Library and EconLit were searched from database inception through 31 August 2017. Eligible studies reported HSUVs elicited using the EQ-5D questionnaire in adults with chronic hepatitis C infection. Study quality and risk of bias were assessed.

Results

Of 1480 records identified, 26 studies were included. The most commonly defined health states described different stages of chronic hepatitis C infection and specific liver-related disease states, including METAVIR score, compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Patients with higher METAVIR scores tended to have lower EQ-5D scores compared to patients with lower METAVIR scores. Patients that achieved sustained virologic responses tended to have higher EQ-5D scores compared to those that did not. A meta-analysis conducted on three studies confirmed that patients with decompensated cirrhosis have significantly lower HSUVs than patients with compensated cirrhosis [mean difference − 0.11 (95% CI − 0.19 to − 0.04)], implying worse HRQoL. However, there was not sufficient evidence to compare how different treatments for chronic hepatitis C infection affect EQ-5D scores.

Conclusions

This study provides a summary of EQ-5D HSUVs for patients with chronic hepatitis C infection, and demonstrates that clinically important disease stages associated with treatment decisions are associated with differences in HRQoL.
Vorheriger Artikel Measurement properties of self-report questionnaires on health-related quality of life and functional health status in dysphonia: a systematic review using the COSMIN taxonomy
Nächster Artikel Health-related quality of life (HRQoL) in beta-thalassemia major (β-TM) patients assessed by 36-item short form health survey (SF-36): a meta-analysis

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Negro, F., & Alberti, A. (2011). The global health burden of hepatitis C virus infection. Liver International, 31(s2), 1–3.CrossRef
3.
Manns, M., Wedemeyer, H., & Cornberg, M. (2006). Treating viral hepatitis C: Efficacy, side effects, and complications. Gut, 55(9), 1350–1359.CrossRef
4.
Seifert, L. L., Perumpail, R. B., & Ahmed, A. (2015). Update on hepatitis C: Direct-acting antivirals. World Journal of Hepatology, 7(28), 2829.CrossRef
5.
Ermis, F., & Tasci, E. S. (2015). New treatment strategies for hepatitis C infection. World Journal of Hepatology, 7(17), 2100.CrossRef
6.
Patrick, D. L., & Deyo, R. A. (1999). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27, 217–232.CrossRef
7.
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., et al. (2015). Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, open-label phase 2 trial. The Lancet, 385(9973), 1075–1086.CrossRef
8.
9.
Kastien-Hilka, T., Abulfathi, A., Rosenkranz, B., Bennett, B., Schwenkglenks, M., Sinanovic, E. (2016). Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis—A systematic review of global literature with focus on South Africa. Health and Quality of Life Outcomes, 42(14), 1–13.
10.
11.
12.
Drummond, M. E., Sculpher, M. J., Torrance G. W., et al. (2005). Methods for the eocnomic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.
13.
Wee, H. L., Machin, D., Loke, W. C., Li, S. C., Cheung, Y. B., Luo, N., et al. (2007). Assessing differences in utility scores: A comparison of four widely used preference-based instruments. Value in Health, 10(4), 256–265.CrossRef
14.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine, 151(4), 264–269.CrossRef
15.
16.
17.
Chong, C. A. K. Y., Gulamhussein, A., Heathcote, E. J., Lilly, L., Sherman, M., Naglie, G., et al. (2003). Health-state utilities and quality of life in hepatitis C patients. American Journal of Gastroenterology, 98(3), 630–638.CrossRef
18.
Bjornsson, E., Verbaan, H., Oksanen, A., Fryden, A., Johansson, J., Friberg, S., et al. (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology, 44(7), 878–887. [Multicenter Study]CrossRef
19.
Samp, J. C., Perry, R., Piercy, J., & Baran, R. W. (2014). Utility values of hepatitis C patients in France: Results by liver disease stage and treatment outcome. Value in Health, 17(3), A279. [Conference Abstract]CrossRef
20.
Samp, J. C., Perry, R., Piercy, J., Wood, R., & Baran, R. W. (2015). Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clinics and Research in Hepatology and Gastroenterology, 39(3), 307–314.CrossRef
21.
Custer, B., Vahidnia, F., Kessler, D., Leparc, G., Krysztof, D., Shaz, B., et al. (2014). Health-related quality of life in us blood donors with and without viral infections. Vox Sanguinis, 107, 97. [Conference Abstract]CrossRef
22.
DeVecchis Wygant, G., Mo, L., Treitel, M., Bhore, R., & Torbeyns, A. (2016). EQ-5D results in Asian patients with HCV G1b receiving DCV + ASV who are IFN intolerant/ineligible. Hepatology International, 10(Suppl 1), S142.
23.
Kaishima, T., Akita, T., Aikata, H., Chayama, K., & Tanaka, J. (2016). Cost-effectiveness analysis related to HCV treatment is possible to be estimated in each province. Hepatology International, 10(Suppl 1), S148–S149.
24.
McDonald, S. A., Hutchinson, S. J., Palmateer, N. E., Allen, E., Cameron, S. O., Goldberg, D. J., et al. (2013). Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. Journal of Hepatology, 58(3), 460–466.CrossRef
25.
Nouvertne, D., Perry, R., & Milligan, G. (2014). Health-related quality of life and productivity impairment in chronic hepatitis C patients in Germany. Journal of Viral Hepatitis, 21, 34–35. [Conference Abstract]
26.
Pol, S., Chevalier, J., Branchoux, S., Perry, R., Milligan, G., & Gaudin, A. F. (2015). Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the UK and Germany. Journal of Hepatology, 62, S606. [Conference Abstract]CrossRef
27.
Nwankwo, C. U., Sung, A. H., & Pike, J. S. (2014). Self-reported health related quality of life of hepatitis C virus (HCV) genotype 1 patients with and without comorbid conditions. Value in Health, 17(7), A369–A370.CrossRef
28.
Schafer, A., Wittchen, H. U., Backmund, M., Soyka, M., Golz, J., Siegert, J., et al. (2009). Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction, 104(4), 630–640.CrossRef
29.
Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.CrossRef
30.
Schwarzinger, M., Cossais, S., Deuffic-Burban, S., Pol, S., Fontaine, H., Larrey, D., et al. (2015). EQ-5D utility index in French patients with chronic hepatitis C (CHC) infection: Severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage. Journal of Hepatology, 62, S605.CrossRef
31.
Scott, J., Rosa, K., Fu, M., Cerri, K., Peeters, M., Beumont, M., et al. (2014). Fatigue during treatment for hepatitis C virus: Results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases, 14(1), 465.CrossRef
32.
Stepanova, M., Nader, F., Cure, S., Bourhis, F., Hunt, S., & Younossi, Z. M. (2014). Patients’ preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Alimentary Pharmacology and Therapeutics, 40(6), 676–685.CrossRef
33.
Younossi, Z. M., Stepanova, M., Cure, S., Bourhis, F., Nader, F., & Hunt, S. L. (2014). Estimating health status using EQ5D for chronic hepatitis c (CH-C) patients treated with sofosbuvir (SOF) containing regimens. Journal of Hepatology, 1, S308. [Conference Abstract]
34.
Vargas, C. L., Espinoza, M. A., Giglio, A., & Soza, A. (2015). Cost effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis c genotype 1b Naive patients in Chile. PLoS ONE. 10(11), e0141660.CrossRef
35.
Vera-Llonch, M., Martin, M., Aggarwal, J., Donepudi, M., Bayliss, M., Goss, T., et al. (2013). Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Alimentary Pharmacology and Therapeutics, 38(2), 124–133.CrossRef
36.
Yeung, M. W., Young, J., Moodie, E., Rollet-Kurhajec, K. C., Schwartzman, K., Greenaway, C., et al. (2015). Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: A prospective cohort study. HIV Clinical Trials, 16(3), 100–110.CrossRef
37.
Wright, M., & Grieve, R. (2006). Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. (Provisional abstract). Health Technology Assessment. 10, 1–250.CrossRef
38.
Vahidnia, F., Stramer, S. L., Kessler, D., Shaz, B., Leparc, G., Krysztof, D. E., et al. (2017). Recent viral infection in US blood donors and health-related quality of life (HRQOL). Quality of Life Research, 26(2), 349–357.CrossRef
39.
Gschwantler, M., Ferenci, P., Bauer, B., Laferl, H., Bamberger, T., Stauber, R., et al. (2016). Burden of disease in patients with chronic hepatitis C in the Austrian REAL Study. Hepatology, 63(Suppl 1), 466a–467a. [Journal: Conference Abstract]
40.
Huang, R., Rao, H., & Wei, L. (2017). Assessment of health-related quality of life and related factors in Chinese patients with chronic hepatitis C virus infection. Hepatology International, 11(Suppl 1), S558. [Conference Abstract]
41.
Kieran, J. A., Adams, R., Chin, J. L., Mushtaq, H., McCormick, P. A., McKiernan, S., et al. (2015). Health-state utilities for patients with chronic Hepatitis C infection. Irish Journal of Medical Science, 184(6 Suppl 1), S230. [Conference Abstract]
42.
Wygant, G., Mo, L., Treitel, M., & Zhao, Y. (2017). Patient reported outcomes in IFN/ribavirin intolerant/ineligible Asian patients from Mainland China receiving daclatasvir + asunaprevir for the treatment of HCV genotype 1b infection. Hepatology International, 11(Suppl 1), S1001–S1002. [Conference Abstract]
43.
MVH Group (1995). The measurement and valuation of health: Final report on the modelling of valuation tariffs. York: Centre for Health Economics, University of York.
44.
Badia, X., Roset, M., Herdman, M., & Kind, P. (2001). A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Medical Decision Making, 21(1), 7–16.CrossRef
45.
46.
47.
48.
49.
Ara, R., & Brazier, J. (2008). Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value in Health, 11(7), 1131–1143.CrossRef
50.
51.
Rowen, D., Brazier, J., Tsuchiya, A., & Alava, M. H. (2012). Valuing states from multiple measures on the same visual analogue sale: A feasibility study. Health Economics, 21(6), 715–729.CrossRef
52.
Gray, A., Clarke, P., & Rivero-Arias, O. (2004). Estimating the association between SF-36 responses and EQ-5D utility values by direct mapping. In Health Economists Studying Group Meeting (HESG), Paris.
53.
Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43, 203–220.CrossRef
54.
Zarate, V., Kind, P., Valenzuela, P., Vignau, A., Olivares-Tirado, P., & Munoz, A. (2011). Social valuation of EQ-5D health states: The Chilean case. Value in Health, 14(8), 1135–1141.CrossRef
55.
Fryback, D. G., Dunham, N. C., Palta, M., Hanmer, J., Buechner, J., Cherepanov, D., et al. (2007). US norms for six generic health-related quality-of-life indexes from the National Health Measurement Study. Medical Care, 45(12), 1162.CrossRef
56.
Dolan, P., Gudex, C., Kind, P., & Williams, A. (1995). A social tariff for EuroQol: Results from a UK general population survey. York: Centre for Health Economics University of York.
57.
Longworth, L., Young, T., Ratcliffe, J., Bryan, S., & Buxton, M. (2001) Economic evaluation of the Transplantation Programme in England and Wales: An assessment of the costs of liver transplantation. Report to the Department of Health.
58.
Bansback, N., Tsuchiya, A., Brazier, J., & Anis, A. (2012). Canadian valuation of EQ-5D health states: Preliminary value set and considerations for future valuation studies. PLoS ONE, 7(2), e31115.CrossRef
59.
Peasgood, T., & Brazier, J. (2015). Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics, 33(11), 1101–1105.CrossRef
Metadaten
Titel
Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis
verfasst von
A. M. Buchanan-Hughes
M. Buti
K. Hanman
B. Langford
M. Wright
L. A. Eddowes
Publikationsdatum
17.09.2018
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 2/2019
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1992-3

Weitere Artikel der Ausgabe 2/2019

Quality of Life Research 2/2019 Zur Ausgabe

Review

Measurement properties of self-report questionnaires on health-related quality of life and functional health status in dysphonia: a systematic review using the COSMIN taxonomy

Brief Communication

Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers

OriginalPaper

Sex differences in predictors of illness intrusiveness in persons with multiple sclerosis

OriginalPaper

Determinants for quality of life trajectory patterns in patients with type 2 diabetes

OriginalPaper

Anxiety, depression and quality of life in chronic obstructive pulmonary disease patients and caregivers: an actor–partner interdependence model analysis

OriginalPaper

Temporal changes in importance of quality of life domains: a longitudinal study in community-dwelling Swiss older people

Premium Partner

    Bildnachweise